Related Experiment Video
Updated: Dec 30, 2025
05:23
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
691
Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial
Su Youn Nam1, Sang Won Lee2, Seong Woo Jeon2
1Department of Gastroenterology, Kyungpook National University Hospital Chilgok, School of Medicine, Kyungpook National University, 807 Hoguk-ro, Buk-gu, Daegu, 41404, Korea. nam20131114@gmail.com.
Digestive Diseases and Sciences
|January 25, 2020
Summary
Eradicating Helicobacter pylori (H. pylori) infection significantly regressed gastric hyperplastic polyps. Persistent H. pylori infection was linked to gastric polyp progression, highlighting the importance of H. pylori eradication.
Area of Science:
- Gastroenterology
- Microbiology
- Oncology
Background:
- Helicobacter pylori infection is strongly associated with gastric hyperplastic polyps.
- Limited randomized controlled trial data exist on the impact of H. pylori eradication on these polyps.
Purpose of the Study:
- To evaluate the efficacy of H. pylori eradication in inducing the regression of gastric hyperplastic polyps.
Main Methods:
- An open-label, single-center, randomized controlled trial was conducted.
- Patients with hyperplastic polyps and H. pylori infection were randomized into eradication and non-eradication groups.
- Gastric polyp regression was assessed via follow-up endoscopy, defined as complete disappearance or >50% size reduction.
Main Results:
- All patients (14) in the H. pylori eradication group showed polyp regression (7 disappeared, 7 reduced size).
- No regression was observed in the non-eradication group (13 patients); polyps remained unchanged, increased in size, or number.
- Mean regression time was 6.8 months, and mean disappearance time was 9.8 months.
Conclusions:
- H. pylori eradication effectively induces regression of gastric hyperplastic polyps.
- Persistent H. pylori infection is associated with the progression of gastric polyps.
More Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
985
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
985
01:26Peptic Ulcer Disease IV: Management
371
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
371
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
476
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
476
01:23Gastritis III: Clinical Manifestations and Management
1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
01:30Peptic Ulcer Disease I: Introduction
687
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
687
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K